ISRAEL- According to a recent study on the adverse effects of the monkeypox vaccine, the majority of vaccine recipients in Israel reported no apparent symptoms.
Since the outbreak started, this is some of the first data to be carefully reported on the vaccine’s side effects and uptake. However, the data does not represent the vaccine’s efficacy, which will take more time to evaluate.
“Most of the side effects reported by the vaccinated are local and mild, which in most cases pass within one to three days,” said Miri Mizrahi Reuveni, Deputy CEO and Head of the Health Division at Maccabi Healthcare Services, which conducted the survey.
According to Maccabi, 62% of 155 immunization participants said they were able to resume their normal routines without experiencing any overarching effects. The remaining 38% experienced negative consequences.
74% of recipients reported pain, including stiffness (22%), regional swelling (7%), and itching (6%), at the injection site.
Most people who had adverse effects said that they persisted for more than 24 hours.
22% of patients with symptoms reported that they are still present now while only 3% of people said their symptoms disappeared in under 24 hours.
Israel now has 208 cases of monkeypox, with 11 more cases found in the last four days, according to the Health Ministry of the nation.
The first case of monkeypox outside of historically endemic African nations was found in London on May 4, which marked the start of the global pandemic.
The World Health Organization (WHO) reports that it has since spread throughout the world, with over 35,000 cases of monkeypox reported from 92 countries and territories, along with 12 fatalities.
Israel now has 208 cases of monkeypox, with 11 more cases found in the last four days, according to the Health Ministry of the nation.
The ministry reported that more than 2,000 at-risk individuals had already received a double-dose immunization against the virus in Israel.
Israel initiated a vaccination program for at-risk groups in the latter part of July, with the shipping of 5,600 doses made by the Danish company Bavarian Nordic. In September, a shipment of 4,400 more dosages is anticipated.
The ministry stated that it was thinking about extending the vaccination requirements to permit greater use of all doses as well as the purchase of additional doses of the vaccine.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
